Optimal Intermittent Administration Interval of parathyroid hormone 1-34 for Bone Morphogenetic Protein-Induced Bone Formation in a Rat Spinal Fusion Model

Tetsutaro Abe
Oita Daigaku Igakubu Fuzoku Byoin

Masashi Miyazaki (miyazakisora@gmail.com)
Oita Daigaku Igakubu Fuzoku Byoin

Toshinobu Ishihara
Oita Daigaku Igakubu Fuzoku Byoin

Shozo Kanazaki
Oita Daigaku Igakubu Fuzoku Byoin

Yuhta Tsubouchi
Oita Daigaku Igakubu Fuzoku Byoin

Masashi Kataoka
Oita Daigaku Igakubu Fuzoku Byoin

Hiroshi Tsumura
Oita Daigaku Igakubu Fuzoku Byoin

Research article

Keywords: Parathyroid hormone, Teriparatide, Bone morphogenetic protein, bone fusion, rat spinal fusion model

DOI: https://doi.org/10.21203/rs.3.rs-54656/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Summary of Background Data. Both bone morphogenetic protein 2 (BMP-2) and parathyroid hormone (PTH) have been used to enhance bone healing. There is still no established opinion as to the optimum dose and administration method. We investigated to clarify the optimal dose and administration method for the combination of BMP-2 and PTH in a rat spinal fusion model.

Methods. A total of 52 rats were performed spinal fusion and were divided into four groups. Group I (n = 10) was implanted with control carrier. Group II (n = 14) was implanted with carrier containing 3 μg of recombinant human BMP-2 (rhBMP-2). Group III (n = 14) was implanted with carrier containing 3 μg of rhBMP-2, followed by injections of PTH three times a week (total, 180μg/kg/week). Group IV (n = 14) was implanted with carrier containing 3 μg of rhBMP-2, followed by injections of PTH six times a week (total, 180μg/kg/week). The rats were euthanized after 8 weeks and their spines were explanted and assessed by manual palpation, radiographs, and high-resolution micro computerized tomography (micro-CT); the spines were also subjected to histological analysis. Serum markers of bone metabolism were also analyzed.

Results. Manual palpation tests showed that the fusion rates of Groups III (28.6%) and IV (35.7%) were considerably higher than those of Group I. Groups III and IV had higher radiographic scores compared to Group I. Micro-CT analysis revealed enhanced bone marrow density expressed as bone volume/tissue volume in Group IV (54.20 ± 2.49%) versus Group I (38.56 ± 7.78%). Serum makers analysis revealed that Group IV had higher osteocalcin and lower tartrate-resistant acid phosphatase-5b than those of Group III. A histological analysis indicated that Group VI had enhanced remodeling.

Conclusions. The combination of rhBMP-2 and PTH enhanced bone fusion and remodeling of newly formed bone in a rat spinal fusion model. More frequent administration may be superior in terms of bone fusion and bone metabolism.

Introduction

There are some reports of bone fusion caused by the combination of spinal arthrodesis and various drugs in the past. Spinal arthrodesis is a fundamental treatment option for spinal pathologies and one of the most common spinal procedures, with more than 20,000 surgeries performed in the United States each year 1). In this procedure, bone grafts are used to restore mechanical stability to the affected spinal segment by providing bridging bone between vertebrae. Because successful bone fusion between unstable spinal segments leads to pain relief and neurologic recovery, the efficacy of this procedure has gained wide acceptance, and the number of these types of surgery has increased annually with the increase in the aged population 2-5).

Bone morphologic proteins (BMPs) are members of the transforming growth factor-β superfamily 6), and are powerful osteoinductive molecules. BMPs also are considered to promote new osteoclast formation since they stimulate the production of receptor activator of nuclear factor kappa-β ligand (RANKL)
osteoblasts and help ensure mature osteoclast survival; therefore, BMPs participate in bone matrix resorption. The osteoinductive effects of recombinant human BMP-2 (rhBMP-2) for spinal fusion have been shown in animal models and clinical trials. Although BMPs are approved for clinical use, clinical trial results have shown that high doses are required to induce adequate bone fusion because of the following reasons: (1) solubility of the molecules, (2) easy diffusion of the molecules away from the fusion site, and (3) in vivo inactivation. In addition, BMPs are expensive; therefore, their usefulness may be limited by their expense. As a result, a number of strategies are being developed to provide a safer, less expensive, and more efficacious spinal fusion using rhBMP-2.

Human parathyroid hormone (PTH) 1-34 is an anabolic drug, and its efficacy as an osteoporosis drug has been widely verified through experimental and clinical studies. Although PTH could have bone resorption effects with continuous administration, it can accelerate bone formation with intermittent administration. PTH can also enhance fracture healing not only in ovariectomized rats but also in intact rats. The clinical use of PTH to accelerate fracture healing has been attempted, and the combination of PTH and BMPs has been shown favor spinal fusion. But the optimal intermittent administration interval of PTH has not been revealed.

We previously reported that the synergic effect of rhBMP-2 and PTH administered systemically as a single dose at the optimal time was efficacious for fracture repair, and significantly enhanced bone fusion in a rat femoral fracture model. The purpose of this study was to clarify the optimal dosing interval and administration method for the combination of rhBMP-2 and PTH in a rat spinal fusion model.

**Material And Method**

**Preparation of matrices**

CollaCote® (Zimmer/dental) is a biodegradable collagen scaffolding used for cellular attachment. Although a collagen sponge has been used clinically as a carrier for rhBMP-2, CollaCote® has an allograft matrix possess hemostatic function that facilitates early clot formation and wound stabilization. The final concentration of rhBMP-2 (Peprotech, Rocky Hill, NJ) was dissolved in phosphatebuffered saline (PBS) buffer (pH 7.5) and applied to CollaCote®. CollaCote® was cut with a scalpel into 5 × 20-mm strips and placed with rhBMP-2 in an Eppendorf tube that was left overnight at 4 °C prior to implantation. Similarly, 100 μL of rhBMP-2-free PBS was dropped in CollaCote® to obtain rhBMP-2-free CollaCote®.

**Study groups**

A total of 52 male Sprague–Dawley rats (8–10 weeks old; CLEA Japan, Inc., Tokyo, Japan) were divided into four groups. Group I (n = 10) included animals that were implanted with control carrier alone. Group II (n = 14) included animals that were implanted with carrier containing 3μg of rhBMP-2. Group III (n = 14) included animals that were implanted with carrier containing 3μg of rhBMP-2, followed by injections of
PTH (Teribone; Asahi Kasei Pharma, Tokyo, Japan) (60 μg/kg) three times a week (total, 180 μg/kg/week). Group IV (n = 14) included animals that were implanted with carrier containing 3 μg of rhBMP-2, followed by injections of PTH (30 μg/kg) six times a week (total, 180 μg/kg/week). Rats in groups III and IV were subcutaneously injected with PTH beginning 1 week after surgery. The injections were continued until immediately before the rats were euthanized.

**Surgical Technique for Constructing the L4-L5 Posterolateral Spinal Fusion Model**

All animal studies were approved by the Oita University animal research committee, and experiments conformed to all guidelines and regulations for the protection of welfare of animals (protocol No. 1624002).

The rats were anesthetized by an intraperitoneal injection containing 0.3–0.4 ml of 0.15 mg/kg medetomidine + 2 mg/kg midazolam + 2.5 mg/kg butorphanol. Disinfect the surgical site with 0.05% Chlorhexidine Gluconate. A posterior midline incision was made on the skin. Next, two separate paramedian incisions were made at 3 mm from the midline in the lumbar fascia and the transverse processes were exposed. The transverse processes of L4 and L5 were decorticated using a low-speed burr. Subsequently, CollaCote with or without rhBMP-2 was implanted on each side. The fascial and skin incisions were closed with a 3–0 absorbable suture. After surgery, the rats were given Gentamicin by intramuscular injection for three successive days. Immediately following surgery and on subsequent days, the rodents received analgesics (buprenorphine subcutaneously and paracetamol). The rodents were housed in separate cages and fed food and water ad libitum and their condition was monitored on a daily basis. The rats were humanly euthanized eight weeks post operatively.

**Manual assessment of fusion**

Eight weeks post-implantation, the explanted spines were manually tested for intersegmental motion by three blinded independent observers. The explanted lumbar spine was palpated gently and the lateral side bending motion at the L4-L5 level was compared with the motion at the adjacent levels above (L3-L4) and below (L5-L6). The absence of motion was considered as successful fusion. Any motion detected between the transverse processes was considered as a failure of fusion. The spine was designated as “not fused” if any of the three observers graded the spine as not fused. The spines were scored as either fused or not on both the right and left sides and the fusion rate was then calculated.

**Radiographic Analysis**

The explanted spines obtained at the 8-week time point were photographed using a Softex X-ray apparatus (Softex CSM-2; Softex, Tokyo, Japan) employing HS Fuji Softex film (Fuji Film, Tokyo, Japan) at 45 cm with 30 kV and 15 mA for 20 s. Fusion between the L4 and L5 transverse processes in each rat was recorded as a percentage of the total area between the L4 and L5 that was filled with new bone. Three blinded independent observers scored the bone formation in each rat using a 5-point scale: 0 = no bone formation; 1 = bone filling in less than 25% of the area; 2 = bone filling in 25–50% of the area; 3 =
bone filling in 50–75% of the area; and 4 = bone filling in 75–100% of the area. The spines were scored on both the right and left sides.

**Micro-CT Analysis**

The spines were scanned by micro-CT using SkyScan 1172 (Bruker microCT, Kontich, Belgium) with a voxel size of 20 mm. The data were collected at 100 kV and 100 mA and reconstructed using the cone-beam algorithm. Each spine was set on the object stage and sample scanning was performed over a 180° rotation with an exposure time of 105 ms. A cylindrical volume of interest with a diameter of 20 mm and a height of 27 mm, which displayed the micro-structure of the rat vertebra as comprised of cortical and cancellous bone, was selected. Data analysis of the area from the top of the L4 transverse processes to the bottom of the L5 transverse processes, including the vertebrae, was performed using the CT Analyzer software (Bruker microCT). The spines were analyzed on both the right and left sides. In the bone mineral density (BMD), tissue volume (TV), bone volume (BV), trabecular thickness (Tb. Th), trabecular spacing (Tb. Sp), and bone volume fraction (BV/TV, %) were measured.

**Analysis of Serum Markers of Bone Metabolism**

Just prior to euthanization of the animals, blood samples were collected and stored at -80℃ until the serum markers of bone metabolism were analyzed. Serum markers of bone metabolism were analyzed with use of an enzymelinked immunosorbent assay specific for osteocalcin (Osteocalcin High Sensitive EIA kit [rat]; Takara Bio, Shiga, Japan) and tartrate-resistant acid phosphatase-5b (TRACP5b) (RatTRAP Assay; Immunodiagnostic Systems), according to the manufacturer’s instructions.

**Histological Analysis**

Eight weeks post implantation, the spines were dissected and the specimens were fixed in 40% ethanol, decalcified using standard 10% decalcifying solution HCl (Cal-Ex; Fischer Scientific, Fairlawn, NJ.), washed with running tap water, and then transferred to 75% ethanol. Serial sagittal sections near the transverse processes were cut carefully at the level of the transverse process on both the right and left sides. The specimens were embedded in wax for sectioning. Sagittal sections (5 mm) were cut from the paraffin blocks using a microtome (LS-113; DAIWA-KOKI, Saitama, Japan). The sections were stained with hematoxylin and eosin for basic morphology. Three blinded independent observers scored histological bone formation. Histological fusion was defined as bony trabeculae bridging from one transverse process to the next. Fusion masses were assessed and the extent of new bone formation was scored using the following scoring criteria: 1 = fibrocartilage tissue filling less than 25% of the gap area; 2 = fibrocartilage tissue filling 25–50% of the gap area; 3 = fibrocartilage and bone tissue filling 75–99% of the gap area; 4 = bridged with bone tissue, but the fusion masses are comprised of thin trabecular bone; and 5 = completely bridged with abundant mature bone tissue. The spines were scored on both the right and left sides.

**Statistical methods**
The computer program Statistical Package for the Social Sciences (SPSS) (V13; IBM Corporation, Armonk, NY) was used for statistical analysis. Analysis of variance was used for statistical analysis. p values <0.05 were considered significant. A kappa statistic was calculated as a measure of the interobserver reliability of the three independent blinded observers. The kappa statistic corrects the observed agreement for possible chance agreement among observers. Agreement was rated as follows: poor, k=0–0.20; fair, k=0.21–0.40; moderate, k=0.41–0.60; substantial, k=0.61–0.80; and excellent, k>0.81. A value of one indicated absolute agreement, whereas a value of 0 indicated agreement no better than chance.

Results

No abnormal behavior or neurological deficits were noted in any of the 52 rats before or after the surgical procedure or at the time of euthanasia. No adverse events have been identified in the groups receiving BMP-2, PTH, and in the control group.

Manual Palpation

Table 1 shows the proportion of subjects in each Group that achieved fusion according to the three independent evaluators. Consistent agreement (κ = 0.864) was noted among the three independent observers who performed manual palpation.

8 segments in Group III (n=14, segments=28) were assessed as fused (fusion rate, 28.6%) and 10 segments in Group IV (n=14, segments=28) exhibited fusion (fusion rate, 35.7%), while 2 segments in Group II (n=14, segments=28) exhibited fusion (fusion rate, 7.1%). None of the spines in Group I (n=10, segments=20) were fused (fusion rate, 0%). The subjects in Group III and IV had higher fusion rates than in the Group I and II. There was no significant difference between the manual assessment scores of Groups I and II, whereas significantly higher fusion rates were observed in Group III and IV than in Groups I (p<0.05). No significant difference was found between groups III and IV.

Radiographic analysis

Radiographs of the spines were obtained at 8 weeks. Consistent agreement (κ = 0.812) was noted among the three independent observers who graded the radiographs. The spines were scored on both the right and left sides. The average evaluation scores for each Group are shown in Table 2, and the representative anteroposterior (AP) radiographs of the representative case in each Group at 8 weeks are shown in Figure 1. At eight weeks postoperatively, Group III and IV showed evidence of bone formation between the L4 and L5 transverse processes and bony bridging was detected. Mineralized callus bridging between the L4 and L5 transverse processes was detected in Group II, although the amount of callus was deemed insufficient. Group I showed no evidence of bone formation. The scores of Groups III and IV were significantly higher than those of Group I (p<0.05).

Micro-CT analysis
A computer analysis of the micro-CT images revealed the volume of new bone and the quality of the spinal fusion area. The average micro-CT data based on the histomorphometry of each Group are shown in Tables 3 and 4. The statistical analysis revealed a statistical difference in the variance in the bone volume percentage. The bone volume percentage of Group II was larger than that of Group I (p = 0.023). Trabecular thickness (p = 0.041) and trabecular spacing (p = 0.026) also had statistical significance between Group II and III. Trabecular thickness (p = 0.040) had statistical significance between Group II and III.

**Serum Markers of Bone Metabolism**

Enzyme-linked immunosorbent assay demonstrated that serum levels of osteocalcin had no significant differences in each Group II, III, and IV compared with Group I. On the other hand, a significant difference was found between Group III and Group IV (p<0.05) (Figure 2). Identically, serum levels of TRACP5b had no significant differences in each Group II, III, and IV compared with Group I. Whereas a significant difference was found between Group III and Group IV (p < 0.05) (Figure 3).

**Histological analysis**

Histological analysis of Group I showed a paucity of new bone formation and no evidence of fusion (Figure 4A, B). These images clearly demonstrate muscle between the transverse processes for both specimens. Occasional evidence of new bone formation was observed, originating either from the decorticated transverse process or normal remodeling. Group II showed distribution of cartilaginous tissue, but there was fibrosis tissue and muscle fiber between the transverse processes and no evidence of bone fusion (Figure 5A, B). Analysis of Group III showed distribution of cartilaginous tissue and immature bone formation, but no woven bone between the transverse processes (Figure 6A, B). Group IV showed new bone formation bridging the transverse processes demonstrating mature osteoid tissue and trabeculae contracts (Figure 7A, B). Histological fusion scores are shown in Table 5. The spines were scored on both the right and left sides. Group III and IV had significantly higher histological scores than the Group I (p<0.05). Consistent agreement (k=0.862) was noted among the three independent observers.

**Discussion**

In the present study, we investigated the optimal intermittent administration interval dosing of PTH using BMPs for spinal fusion in a rat spinal fusion model. Posterolateral lumber fusion in rats has been well established as an acceptable model for measuring bone growth and manual palpation is the most sensitive and specific method for assessing spinal fusion\(^{25-32}\). Although a generous amount of PTH effectively demonstrated fracture healing in rat models\(^19\), the clinical application for humans must be much larger. A clinical dose of PTH to treat human osteoporosis is 20–40 μg/day in Japan and the USA. A dose of 5 μg/kg/day seemed ineffective for changing the mechanical properties in a rat\(^20\). Morimoto et al. reported successful spinal fusion with weekly doses of 180 μg/kg/week PTH in a rat model of spinal fusion\(^33\). Therefore, we adopted 180 μg/kg/week (3 times/week and 6 times/week). Due to the
difference in metabolism between humans and rats, it is assumed that the 6 times weekly administration Group is approximately 2 times weekly administration in human, and the 3 times weekly administration Group is approximately once weekly administration in human 34).

Recent studies of the interactions between PTH and BMP showed that there are two types of interactions between PTH and rhBMP-2 35). The first is a mechanism that occurs through a complex comprising PTH type-1 receptors (PTH1R), low-density lipoprotein receptor-related protein 6 (LRP6) within the canonical Wnt pathway, and BMP antagonists. Endocytosis of the complex suppresses negative feedback of BMP antagonists, thereby stimulating BMP signaling. Through that mechanism, PTH enhances the differentiation of mesenchymal stem cells (MSCs) into osteoblasts. The second is a mechanism that occurs through peroxisome proliferator-activated receptor gamma (PPARγ). Excessive BMP signaling results in downregulation of the Wnt pathway through sclerostin. The downregulated Wnt pathway results in increased PPARγ, which persuades MSCs to differentiate into adipocytes. PTH could activate the Wnt pathway and suppress PPARγ. Morimoto et al. reported synergistic anabolic effects with the concomitant use of intermittent PTH and locally applied rhBMP-2 in a rat model of spinal fusion 33), in their study, the combination increased fusion rates and improved the quality of the newly formed bone. In the present study, Groups III and IV had significantly better fusion rates than Group I according to the manual palpation tests, and higher radiographic evaluation scores. They also had a better fusion rate than Group II. The micro-CT analysis indicated that Group III and IV had significantly higher BV/TV scores compared to Group I, which indicated increased bone marrow density. Trabecular thickness (Tb. Th) and trabecular number (Tb. N) also showed statistical differences, so PTH has the effect of strengthening the trabecular bone structure, and the effect may be stronger when administered 6 times a week. Although no significant difference was observed, Group IV tended to be superior to Group II.

Earlier studies investigating the long-term daily administration of PTH in ovariectomized rats 36,37) did not report its effects on bone metabolism markers. However, in a prior study, daily administration of PTH at a dose of 30 µg/kg for 12 months led to a 40 % increase in osteocalcin, a bone formation marker, relative to the control Group 38). In our study, six-times-weekly administration of PTH at 30 µg/kg (180 µg/kg/week) elicited a similar increase in osteocalcin. We observed decrease in serum TRAP5b following six-times-weekly administration of teriparatide compared with control Group. On the other hand, in the three-times-weekly administration Group, neither osteocalcin nor TRAP5b was significantly different from the control Group. These results suggest that daily administration of PTH increases bone formation and bone resorption, with enhanced bone turnover favoring bone formation, whereas six-times-weekly administration of teriparatide may enhance bone formation with no accompanying increase in bone resorption, so six times a week dosing may be the best.

The results of the histological analysis revealed that Group III and IV had well developed bone trabeculae and bone marrow and mature osteocytes that were not seen in Groups I and II. Group IV also showed an almost normal appearance of the bone marrow compared to Group III. This could be evidence of enhanced remodeling caused by more frequent PTH administration.
Limitations of the present study was that we could not see the bone fusion process because we decided to sacrifice the rats at 8 weeks after surgery, when complete bone fusion of the spine had occurred. Despite this, we chose to use a practical dose of rhBMP-2 and PTH in the clinical setting, which was advantageous to the study. Although we cannot directly apply our findings to humans because the rat has different biological reactions to drugs, we believe that the results of the current study provide further evidence for understanding the effects of these therapeutic agents.

In conclusion, the combination of abundant rhBMP-2 and PTH enhanced bone fusion and remodeling of newly formed bone in a rat spinal fusion model. More frequent administration may be superior in terms of bone formation.

**Abbreviations**

BMP-2: Bone morphogenetic protein 2; BMPs: Bone morphogenetic proteins; BV: bone volume; LRP6: lipoprotein receptor-related protein 6; PBS: phosphate-buffered saline; PPARγ: peroxisome proliferator-activated receptor gamma; PTH: Parathyroid hormone; PTH1R: PTH type-1 receptors; rhBMPs: recombinant human BMPs; Tb.N: trabecular number; Tb.Th: Trabecular thickness; TV: tissue volume

**Declarations**

**Acknowledgements**

None.

**Funding**

This work was supported by JSPS KAKENHI Grant Number JP16K10829.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Authors’ contributions**

TA, SK, TI, and NN carried out the operation. HT conceived of the study design. TA, MM, YT, MK, and HT interpreted the data and drafted the manuscript. All authors read and approved the final manuscript.

**Ethics approval**

This study was conducted in accordance with the Declaration of Helsinki. Approval was obtained from the Oita University animal research committee prior to animal experimentation (Oita University institutional Animal Ethics Committee no.1624002).

**Consent for publication**
Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976) 2002;27:S26–31.
2. Bridwell KH, Sedgewick TA, O'Brien MF, Lenke LG, Baldus C. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord 1993;6:461–72.
3. McGuire RA, Amundson GM. The use of primary internal fixation in spondylolisthesis. Spine (Phila Pa 1976) 1993;18:1662–72.
4. West JL, Bradford DS, Ogilvie JW. Results of spinal arthrodesis with pedicle screw-plate fixation. J Bone Joint Surg Am 1991;73:1179–84.
5. Zdeblick TA. A prospective, randomized study of lumbar fusion. Preliminary results. Spine (Phila Pa 1976) 1993;18:983–91.
6. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995;10:1681–90.
7. Okamoto M, Murai J, Yoshikawa H, Tsumaki N. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 2006;21:1022–33.
8. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528–34.
9. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002;27:2662–73.
10. Suh DY, Boden SD, Louis-Ugbo J, Mayr M, Murakami H, Kim HS, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (Phila Pa 1976) 2002;27:353–60.
11. Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 2002;31:1067–74.
12. Glassman SD, Carreon L, Djurasovic M, Campbell MJ, Puno RM, Johnson JR. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 2007;7:44–9.
13. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic
protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006;31:2534–9.

14. Louis-Ugbo J, Kim HS, Boden SD, Mayr MT, Li RC, Seeherman H, et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2000;20:1050–9.

15. Hock JM, Gera I, Fonseca J, Raisz LG. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988;122:2899–904.

16. Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 1995;16:357–65.

17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41.

18. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97:3097–106.

19. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999;14:960–8.

20. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731–41.

21. Ioan A Lina, Varun Puvanesarajah, Jason A Liauw, Sheng-fu L Lo, et al. Quantitative Study of Parathyroid Hormone (1-34) and Bone Morphogenetic protein-2 on Spinal Fusion Outcomes in a Rabbit Model of Lumbar Dorsolateral Intertransverse Process Arthrodesis. Spine (Phila Pa 1976) 2014;39:347–55.

22. Kanezaki S, Miyazaki M, Ishihara T, Notani N, Abe T, Tsumura H, et al. Enhancement of the effects of intermittent parathyroid hormone (1-34) by bone morphogenetic protein in a rat femoral open fracture model. J Orthop Surg Res 2019;29:403.

23. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88:1431–41.

24. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010;16: CD006950.

25. Kodera R, Miyazaki M, Yoshiiwa T, et al. Manipulation of anabolic and catabolic responses with bone morphogenetic protein and zoledronic acid in a rat spinal fusion model. Bone 2014;58: 26-32.

26. Hayashi T, Lord EL, Suzuki A, et al. A comparison of commercially available demineralized bone matrices with and without human mesenchymal stem cells in a rodent spinal fusion model. J
27. Kaito T, Johnson J, Ellerman J, et al. Synergistic effect of bone morphogenetic proteins 2 and 7 by ex vivo gene therapy in a rat spinal fusion model. J Bone Joint Surg Am 2013;95: 1612-1619.

28. Miyazaki M, Sugiyama O, Tow B, et al. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Spinal Disord Tech 2008;21: 372-379.

29. Miyazaki M, Zuk PA, Zou J, et al. Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine (PhilaPa 1976) 2008;33: 863-869.

30. Miyazaki M, Sugiyama O, Zou J, et al. Comparison of lentiviral and adenoviral gene therapy for spinal fusion in rats. Spine (PhilaPa 1976) 2008;33: 1410-1417.

31. Ishihara T, Miyazaki M, Notani N, et al. Locally applied simvastatin promotes bone formation in a rat model of spinal fusion. J Orthop Res 2017;35: 1942-1948.

32. Miyazaki M, Morishita Y, He W, et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats. Spine J 2009;9: 22-30.

33. Morimoto T, Kaito T, Kashii M, Matsuo Y et al. Effect of Intermittent Administration of Teriparatide (Parathyroid Hormone 1-34) on Bone Morphogenetic Protein-Induced Bone Formation in a Rat Model of Spinal Fusion. J Bone Joint Surg Am 2014;96: e107.

34. Kawabata R, Isogai Y, Takakura A, et al. Three-Times-Weekly Administration of Teriparatide Improves Vertebral and Peripheral Bone Density, Microarchitecture, and Mechanical Properties Without Accelerating Bone Resorption in Ovariectomized Rats. Calcif Tissue Int 2015;97: 156-168.

35. Yu B, Zhao X, Yang C, Crane J, Xian L, Lu W, Wan M, Cao X. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J Bone Miner Res 2012;27: 2001-14.

36. Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 1997;138: 4330-4337.

37. Sato M, Ma YL, Hock JM, Westmore MS, Vahle J, Villanueva A, Turner CH. Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J Pharmacol Exp Ther 2002;302: 304-313.

38. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 2006;79: 262-272.

Tables

Table 1. Assessment of Spinal Fusion Via Manual Palpation.
### Table 2. Radiographic Scores at 8 weeks.

| Treatment Group | No. studied radiographically | Score at 8 weeks (mean ± SD) |
|-----------------|-----------------------------|-----------------------------|
| Carrier alone   | 20                          | 0.11 ± 1.41                 |
| 3μg rhBMP-2     | 28                          | 0.48 ± 1.55                 |
| 3μg rhBMP-2 + PTH (3 times/week) | 28          | 1.75 ± 1.37*                |
| 3μg rhBMP-2 + PTH (6 times/week) | 28          | 2.11 ± 1.21*                |

*p < 0.05 (vs Group I)

### Table 3.1. Micro-CT Based Histomorphometry of Spines at 8 weeks.

| Treatment Group | No. Assessed Manually for Fusion | No. Assessed as Fused | Fusion Rate (%) |
|-----------------|---------------------------------|-----------------------|-----------------|
| Carrier alone   | 20                              | 0                     | 0               |
| 3μg rhBMP-2     | 28                              | 2                     | 7.1             |
| 3μg rhBMP-2 + PTH (3 times/week) | 28          | 8                     | 28.6*           |
| 3μg rhBMP-2 + PTH (6 times/week) | 28          | 10                    | 35.7*           |

*p < 0.05 (vs Group I)
| Treatment Group | TV (mm$^3$)     | BV (mm$^3$)     | BV/TV (%)   |
|-----------------|-----------------|-----------------|-------------|
| Group I         | Carrier alone   | 123.71 ± 6.88   | 47.44 ± 8.56 | 38.56 ± 7.78 |
| Group II        | 3μg rhBMP-2     | 119.87 ± 13.30  | 44.19 ± 9.45 | 37.05 ± 7.77 |
| Group III       | 3μg rhBMP-2 + PTH (3 times/week) | 114.96 ± 7.45  | 49.19 ± 8.80 | 42.97 ± 8.29 |
| Group IV        | 3μg rhBMP-2 + PTH (6 times/week) | 108.13 ± 12.84 | 58.82 ± 9.68 | 54.20 ± 2.49* |

TV, tissue volume; BV, bone volume; BV/TV, bone volume fraction.

*p < 0.05 (vs Group I)

Table 3.2. Micro-CT based histomorphometry of spines at 8 weeks.

| Treatment Group | Tb. Th (mm)     | Tb. N (1/mm)    | Tb. Sp (1/mm) |
|-----------------|-----------------|-----------------|---------------|
| Group I         | Carrier alone   | 0.22 ± 0.05     | 1.70 ± 0.04   | 0.41 ± 0.11   |
| Group II        | 3μg rhBMP-2     | 0.21 ± 0.06     | 1.81 ± 0.14   | 0.46 ± 0.13   |
| Group III       | 3μg rhBMP-2 + PTH (3 times/week) | 0.21 ± 0.06     | 2.11 ± 0.31*  | 0.38 ± 0.14   |
| Group IV        | 3μg rhBMP-2 + PTH (6 times/week) | 0.30 ± 0.03*    | 1.84 ± 0.29   | 0.20 ± 0.05*  |

Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular spacing.

*p < 0.05 (vs Group I)

Table 4. Histologic fusion score at 8 weeks.
| Treatment Group                                      | Score at 8 weeks (mean ± SD) |
|------------------------------------------------------|------------------------------|
| Group ICarrier alone                                 | 0.10 ± 1.02                  |
| Group II3μg rhBMP-2                                   | 0.68 ± 1.33                  |
| Group III3μg rhBMP-2 + PTH (3 times/week)            | 2.66 ± 1.21*                 |
| Group IV3μg rhBMP-2 + PTH (6 times/week)             | 3.15 ± 1.73*                 |

*p < 0.05 (vs Group I)